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Abstract
Background and Aims—A new gene expression profile test may distinguish eosinophilic 
esophagitis (EoE) and gastroesophageal reflux disease (GERD), but the optimal tissue preparation 
and biopsy location are unknown. We aimed to determine if formalin-fixed paraffin-embedded 
(FFPE) and RNA-later (RNAL) preserved specimens from newly diagnosed EoE patients have 
equivalent gene expression scores and whether scores vary by esophageal biopsy location.
Methods—We analyzed prospectively collected and banked esophageal biopsies from EoE 
patients and GERD controls. Paired FFPE and RNAL samples from the distal, mid, and proximal 
esophagus were used. RNA was extracted, and gene expression for a previously constructed 96 
gene panel was quantified with a summary expression score. Scores were compared between EoE 
and GERD patients, between FFPE and RNAL samples, and between the different esophageal 
locations.
Results—A total of 72 samples, representing paired FFPE and RNAL specimens from 9 EoE 
cases and 3 GERD controls, were analyzed. Overall median gene expression scores were similar 
between FFPE and RNAL (238 vs 227; p=0.64), correlation was excellent between FFPE and 
RNAL (Spearman’s rho=0.90; p<0.001), and there were no differences by biopsy level. Median 
gene scores distinguished EoE from controls (134 vs 402; p=0.02), and overall agreement between 
preservation methods and EoE case status was perfect (kappa=1.0; p<0.001).
Conclusions—Gene expression scores were equivalent in FFPE and RNAL, and were also 
similar across three esophageal locations. This implies that a single biopsy in either FFPE or 
RNAL from anywhere in the esophagus may have the potential for genetic diagnosis of EoE.
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Introduction
Eosinophilic esophagitis (EoE) is a chronic immune-mediated clinicopathologic condition 
[1]. In order to diagnose EoE, current criteria (EoE) require symptoms of esophageal 
dysfunction and persistent esophageal eosinophilia (at least 15 eosinophils per high power 
field [eos/hpf]) after a high-dose proton pump inhibitor (PPI) trial, and with other potential 
causes of eosinophilia excluded [2, 3]. While these appear to be straightforward, in clinical 
practice the differentiation between EoE and GERD is difficult. There are no 
pathognomonic features of EoE, symptoms such as dysphagia, heartburn, and chest pain can 
both be present in both GERD and EoE, and even high levels of esophageal eosinophilia are 
not specific [1, 4–12]. Moreover, there is a complicated relationship between EoE and 
GERD, and both conditions can coexist in some patients [13].
Because of this difficulty, there has been extensive research interest in distinguishing the 
two conditions. To date, there has been examination of symptom scores [9, 14–16], tissue 
biomarkers [10, 17–24], and non-invasive biomarkers [25–28], but few have been clinically 
validated and none are in routine practice. Recently, a molecular diagnostic approach has 
been reported [29]. Based on the previously described EoE transcriptome [30], this new test 
selected 96 of the most differentially expressed genes in EoE and created a summary score 
that is highly accurate for separating EoE from GERD, even with a single biopsy [29]. 
However, the optimal strategy for tissue preparation and the location for obtaining the 
biopsy in the esophagus are unknown.
The aim of this study was to determine if formalin-fixed paraffin-embedded (FFPE) and 
RNA-later preserved (RNAL) specimens from newly diagnosed EoE patients would have 
equivalent results on the gene expression profile panel, and whether gene expression scores 
would vary by biopsy location in the proximal, mid, or distal esophagus. We hypothesized 
that there would be no differences between the two tissue preservation methods, but that 
differences might be detected by biopsy location.
Methods
Study subjects and specimen collection
This was a case-control study analyzing biospecimens that were prospectively obtained and 
stored in the University of North Carolina (UNC) EoE Patient Registry and Biobank. This 
resource was created and maintained during prospective investigations of EoE from 2009–
2014 [20, 31–33], where subjects were enrolled if they had symptoms of dysphagia, 
gastroesophageal reflux disease (GERD), or suspected EoE. These studies were approved by 
the UNC IRB, and all study subjects provided informed consent for participating prior to 
undergoing endoscopy, and this included consent for future use of stored specimens. The 
present studying analyzing the banked specimens was also approved by the UNC IRB.
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Patients with EoE were diagnosed as per consensus guidelines [2, 3]. Specifically, they had 
to have symptoms of esophageal dysfunction (dysphagia, food impaction, heartburn, chest 
pain), esophageal biopsies with 15 eos/hpf that persisted after a high-dose PPI trial (20–40 
mg twice daily of any of the available PPIs, prescribed at the discretion of their clinician), 
and exclusion of other potential causes of esophageal eosinophilia. GERD controls were 
patients who did not meet criteria for EoE diagnosis, but who had heartburn- or reflux-
predominant symptoms.
At the time of the endoscopy, research protocol biopsies from all subjects were obtained in 
order to bank tissue for future use. We obtained specimens from the distal (3 cm above the 
gastroesophageal junction [GEJ]), mid (10 cm above the GEJ), and proximal (15 cm above 
the GEJ) esophagus using standard large capacity forceps (RJ4; Boston Scientific, 
Marlborough, MA). At each level, one biopsy fragment was placed in formalin and 
subsequently embedded in paraffin, and one was placed in RNA Later (RNAL; Life 
Technologies/Thermo-Fisher Scientific, Grand Island, NY), frozen, and stored at −80°C. For 
this study, paired FFPE and RNAL samples from each esophageal level were selected for 
each patient (6 samples per patient).
In addition to tissue, patient demographics, symptoms, endoscopic findings, and final 
diagnoses were also recorded prospectively. Further, the esophageal eosinophil counts were 
determined based on our previously validated methodology [34]. The maximum eosinophil 
density (eos/mm2) was quantified in five high power fields and then converted to an 
eosinophil count (eos/hpf) based on a microscopy field size of 0.24mm2, the most 
commonly reported size in the literature [35].
RNA extraction and gene expression
For the FFPE tissue, 5 sections 10 microns thick were cut for RNA extraction. For the 
RNAL samples, the entire biopsy (approximately 8mm3) was used. Each sample was 
processed with standard techniques to extract RNA. In brief, for RNAL samples, the 
miRNeasy mini RNA extraction kit (Qiagen, Valencia, CA) was used. The biopsies were 
transferred to a microtube and macerated in a small volume of QIAzol Lysis Reagent with a 
micropestle (Fisher Sci, Pittsburgh, PA). After addition of chloroform, mixing, and 
centrifugation, the aqueous phases were mixed with ethanol and then transferred to a 
QIAcube (Qiagen) preloaded with RNeasy mini columns for purification. For FFPE 
samples, samples were de-paraffined with xylene and and digested with Proteinase K and 
lysis buffer (miRNeasy FFPE kit, Qiagen). The digested samples were then passed thru 
gDNA eliminator columns and then transferred to the QIAcube preloaded with RNeasy 
MinElute columns for purification. RNA extraction from FFPE samples was 100% 
successful provided that there was adequate tissue, defined as the equivalent of 1 standard-
sized biopsy specimen. RNA concentration purity was measured by NanoDrop spectrometry 
(ThermoFisher) and then reverse transcribed into cDNA using iScript cDNA Synthesis kit 
(Bio-Rad, Hercules, CA) as per the manufacturer’s instructions.
Next, gene expression for a previously constructed 96 gene panel [29] was quantified 
(Eosinophilic Diagnostic Panel [EDP], Diagnovus, Nashville, TN). Specifically, a set of 
TaqMan probes for the 96 genes (including two housekeeping genes, GAPDH and 18S 
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rRNA), were pre-spotted on 384 well fluidic cards (TaqMan Low Density Array Cards; 
TLDA, Life Technologies, Foster City, CA). The qPCR was performed on a ViiA7 cycler 
(Life Technologies) to determine gene expression levels measured as Ct.
Finally, using this expression data, a summary score was calculated by subtracting the 
housekeeping gene from the Ct value of each gene of interest to acquire the ΔCT and then 
summing their absolute values of the upregulated and downregulated genes separately, as 
previously described [29]. A difference of the two sums was used to calculate the EDP score 
with a score <333 diagnostic for EoE.
Statistical analysis
Descriptive statistics were used to summarize demographic, endoscopic, and histologic 
characteristics. The median of the maximum esophageal eosinophil counts were calculated 
both overall and for each esophageal level. Median gene expression scores were also 
calculated overall and for each esophageal level, for both FFPE and RNAL preservation 
methods. The overall score in a given individual was defined as the mean of the scores from 
all levels. Using non-parametric methods (Wilcoxon rank-sum; Wilcoxon sign-rank) the 
median gene scores were compared between the EoE and GERD groups, between FFPE and 
RNAL samples, and between the different esophageal locations. We also assessed for 
differences in individual gene expression by biopsy location and preservation method, 
requiring any differentially expressed genes to pass false discovery rate [36]. Spearman’s 
correlation was performed between the FFPE and RNAL gene scores, as well as between the 
gene scores and esophageal eosinophil counts, both overall and by esophageal level. Finally, 
agreement between EoE case status (as defined by the consensus diagnostic guidelines [2, 
3]) and gene score was determined using the kappa coefficient, both overall and by 
esophageal level. All analyses were performed with Stata 9.2 (StataCorp, College Station, 
TX).
Results
Patient characteristics and samples
A total of 72 samples, representing paired FFPE and RNAL specimens from the proximal, 
mid, and distal esophagus from each of 9 EoE cases and 3 GERD controls, were analyzed 
for this study. Those with EoE were younger than GERD controls (median 34 vs 62 years; p 
= 0.03), all had dysphagia, and typical endoscopic findings such as rings, furrows, plaques, 
and edema were common (Table 1). The median of the maximum eosinophil count was 80 
eos/hpf in the EoE group and 0 eos/hpf in the controls (p < 0.001). For the controls, two 
subjects had normal biopsies with no esophageal eosinophilia, and one had a biopsy 
showing 6 eosh/hpf. For the EoE cases, eosinophil counts were high at all esophageal levels 
(50, 60, and 49 eos/hpf for the proximal, mid, and distal esophagus, respectively).
Gene scores by preservation methods and biopsy location
When RNAL samples were compared to FFPE samples for the entire study population, there 
were no significant differences in the median gene scores either overall or by biopsy 
location (Figure 1). For example, overall median gene scores were 227 for RNAL and 238 
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for FFPE (p = 0.64), and scores in the mid esophagus were 242 and 264, respectively (p = 
0.43).
In addition, there were statistically significant correlations between the RNAL and FFPE 
scores, both overall and by biopsy location (Figure 2). For example, Spearman’s rho was 
0.90 for the overall correlation (p < 0.001), and 0.87 in the mid esophagus (p < 0.001). 
There were no differences in the expression of individual genes (none passed false detection 
rate) either by biopsy location or by tissue preservation type (gene array data are shown in 
the Supplemental Figure).
EoE diagnosis by preservation method and biopsy location
Median gene scores were significantly different between the EoE cases and the controls 
(Table 1). For RNAL, EoE cases had a median score of 134 compared to 402 in the controls 
(p = 0.02), and for FFPE, the median scores were 223 and 362, respectively (p = 0.01). 
Additionally, there were no differences in these scores by preservation method among cases 
alone (p = 0.21) or among controls alone (p = 0.29). Using a score <333 as the threshold for 
diagnosis of EoE, overall agreement between preservation methods and EoE case status was 
perfect, with a kappa of 1.0 (p < 0.001; Figure 3). Agreement was also excellent to perfect at 
each esophageal level, with kappas ranging from 0.8 to 1.0 (p ≤ 0.01 for all comparisons).
There were also significant inverse correlations between the esophageal eosinophil count 
and the gene score for both RNAL and FFPE, both overall and at all esophageal levels 
(Figure 4). Specifically, higher eosinophilic counts were associated with lower gene scores, 
and this association held regardless of case or control status. For example, there was one 
EoE subject with low proximal and mid esophageal eosinophil counts, but high distal counts 
(3, 6, and 110 eos/hpf, respectively). This subject had correspondingly higher gene scores at 
the proximal and mid- levels for both RNAL (468 and 426, respectively) and FFPE (358 and 
330), but lower scores distally (262 for RNAL; 177 for FFPE).
Discussion
The current diagnostic algorithm for EoE requires that both clinical and histologic features 
are present and that competing causes of esophageal eosinophilia are excluded [1–3]. 
However, it remains difficult to distinguish EoE and GERD clinically [4–12], and few 
techniques have been validated to do so [20]. The recent development of a gene expression 
profile test, however, holds great promise for doing just that [29], but whether it was optimal 
to use RNAL- or FFPE-preserved tissue, and whether there was a difference in expression 
by level of the esophagus, was not known. The goals of this study were to determine 
whether gene scores for FFPE specimens were equivalent to those from RNAL, and whether 
there was variability in gene expression scores based on biopsy location. The results were 
strong and consistent. First, RNAL and FFPE gene scores were not statistically different, 
either overall or by biopsy level, and the scores were highly correlated in individual patients, 
regardless of biopsy location. We also did not detect any differences in individual gene 
expression by level. Second, the gene scores almost perfectly distinguished the EoE cases 
from the controls. This has clinical implications for this methodology: one biopsy, 
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regardless of the tissue preservation method or the esophageal location, can potentially be 
used to help diagnose EoE.
The genetic expression profile of patients with EoE, subsequently termed the EoE 
transcriptome, was first described by Blanchard and colleagues in a study of children with 
either active EoE, reflux esophagitis, or normal controls [30]. They demonstrated that there 
were approximately 340 upregulated and 230 downregulated genes characteristic of EoE. 
Additionally, using high-throughput whole transcriptome RNA sequencing techniques, 
Sherrill et al recently expanded the genetic signature of EoE, identifying 1607 differentially 
expressed genes [37]. Identification of differential gene expression led to the development of 
a molecular diagnostic approach for EoE, recently published by Wen et al [29]. In this 
landmark study, the technique was developed in 15 pediatric patients with active EoE and 14 
normal controls, and then confirmed in an independent population of 18 EoE cases and 14 
controls. Additional analysis showed similar results in 12 adults with EoE, and examined 
diagnostic utility in an additional 50 controls and 82 EoE cases. While the majority of 
samples assessed in this study were in RNAL or were fresh tissue, there were a subset tested 
in FFPE that yielded similar results. However, there was no assessment of expression at 
different levels of the esophagus. Our study assessed the same 96 gene panel in an adult 
population, using a similar but commercialized platform. As with the data from the Wen 
study, the panel was nearly perfect in its ability to discriminate EoE cases from controls, and 
we have expanded on their findings with our analysis throughout different levels of the 
esophagus.
This study has some potential limitations, as well as notable strengths, to address. First, this 
was conducted at a single center and included only adults, so we are unable to comment on 
whether the same findings would be seen in other settings or in children. However, the study 
by Wen et al presented comparable results for RNAL and FFPE in a pediatric population 
[29]. Our cases and controls are also not well-matched regarding age, and further validation 
will be needed in an age-matched population. Second, it is possible that the gene score is a 
marker of inflammation and may not be disease specific, but the study design does not allow 
us to comment on the specificity of the gene panel in non-EoE inflammatory conditions, 
including proton pump inhibitor-responsive esophageal eosinophilia. Third, while the 
number of subjects included in this study was small, there were a large number of specimens 
analyzed and the results were robust and consistent across several analysis techniques. 
Moreover, this study utilized prospectively collected and banked tissue samples, with 
standardized protocols and storage methods, from well-characterized EoE cases and GERD 
controls. This is a clinically-relevant population in whom this gene panel could potentially 
be applicable, and allowed for a unique comparison between paired specimens from multiple 
esophageal locations with the two tissue preservation techniques. We were also able to 
perform analyses correlating gene scores with eosinophil counts, both overall and by 
esophageal level. We feel that these strengths outweigh the possible limitations of the study. 
Additionally, while EoE has been shown to be a patchy disease histologically, with wide 
variations in eosinophil counts throughout the esophagus [38], it appears that the gene 
expression may be more consistent. An assessment of gene expression related to variations 
in esophageal eosinophilia should be explored in future studies.
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In conclusion, this analysis of prospectively collected and banked esophageal biopsy 
samples showed that gene expression scores in EoE cases and GERD controls were 
equivalent in FFPE and RNAL tissue. Further, gene expression scores were similar in the 
three esophageal locations tested, and correlated strongly with the esophageal eosinophil 
counts. This implies that a single biopsy in either FFPE or RNAL from anywhere in the 
esophagus may have the potential to be used for genetic diagnosis of EoE.
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Figure 1. 
Comparison of gene expression scores for samples persevered in FFPE (diamonds) vs 
RNALater (circles). (A) Overall score. (B) Score for the proximal esophageal biopsy. (C) 
Score for the mid esophageal biopsy. (D) Score for the distal esophageal biopsy. For all 
graphs, the solid black line represents the median value.
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Figure 2. 
Correlation of gene expression scores measured in FFPE and RNALater. (A) Overall score. 
(B) Score for the proximal esophageal biopsy. (C) Score for the mid esophageal biopsy. (D) 
Score for the distal esophageal biopsy. For all graphs, the dotted lines show the score cut 
point (333) below which a score is consistent with a diagnosis of EoE.
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Figure 3. 
Agreement between case status and tissue preservation method, as measured by kappa, for 
the overall gene score, as well as gene score by esophageal level. Dark gray bars show 
agreement between case status and RNALater, light gray bars show agreement between case 
status and FFPE, and black bars show agreement between RNALater and FFPE.
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Figure 4. 
Correlation between gene expression score, by preservation method, and the peak eosinophil 
count, both for the overall scores and for three esophageal levels. For all graphs, the white 
diamonds are the controls, and the black diamonds are the EoE cases.
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Table 1
Patient characteristics and overall gene scores
GERD (n = 3) EoE (n =9) p*
Age (median, IQR) 62 (39–74) 34 (23–49) 0.03
Male (n, %) 0 (0) 4 (44) 0.49
White (n, %) 3 (100) 8 (89) 1.0
Symptoms (n, %)
 Dysphagia 2 (67) 9 (100) 0.25
 Heartburn 3 (100) 3 (33) 0.18
Endoscopic findings (n, %)
 Rings 0 (0) 9 (100) 0.005
 Furrows 0 (0) 9 (100) 0.005
 Plaques 0 (0) 4 (44) 0.49
 Edema 0 (0) 4 (44) 0.49
 Stricture 2 (67) 6 (67) 1.0
Maximum overall eosinophil count (median eos/hpf, IQR) 0 (0–6) 80 (75–100) 0.01
Maximum eosinophil counts by esophageal level (median eos/hpf, IQR)
 Proximal 0 (0–0) 50 (35–80) 0.01
 Mid 0 (0–4) 65 (21–75) 0.01
 Distal 0 (0–6) 49 (38–100) 0.01
Gene panel scores (medians, IQR)
 RNALater 402 (341–513)** 134 (115–264)** 0.02
 FFPE 362 (358–374) 223 (194–247) 0.01
*
Medians were compared between groups with Wilcoxon rank-sum, and proportions were compared with Fisher’s exact test.
**
No differences detected for comparisons between medial RNALater and FFPE scores for GERD controls (p =0.29) or EoE cases (p = 0.21) using 
Wilcoxon signed-rank
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